By Purchasing Mylan, Teva Gets
Bigger, But Is It Really A
Summary |
Mylan Laboratories may not take a shine to the
unsolicited bid from Teva Pharmaceutical, but the $40 billion
offer certainly appeals to investors, as shares in both drug
makers rose in response.
blogs.wsj.com | 21 April 2015